Search results for "acetylcholine receptor"

showing 10 items of 263 documents

Increased sensitivity of the neuronal nicotinic receptor alpha-2 subunit causes familial epilepsy with nocturnal wandering and ictal fear

2006

Sleep has traditionally been recognized as a precipitating factor for some forms of epilepsy, although differential diagnosis between some seizure types and parasomnias may be difficult. Autosomal dominant frontal lobe epilepsy is characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements and has been associated with mutations of the α4 and β2 subunits of the neuronal nicotinic acetylcholine receptor. We performed a clinical and molecular genetic study of a large pedigree segregating sleep-related epilepsy in which seizures are associated with fear sensation, tongue movements, and nocturnal wandering, closely resembling nightmares and sleep …

AdultMalemedicine.medical_specialtyAdolescentSomnambulismMolecular Sequence DataMutation MissenseAutosomal dominant nocturnal frontal lobe epilepsyReceptors NicotinicBiologymedicine.disease_causeLigandsNicotinicArticleEpilepsyBIO/09 - FISIOLOGIAInternal medicineAcetylcholine; Adolescent; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Epilepsy; Female; Humans; Ligands; Male; Molecular Sequence Data; Mutation Missense; Neurons; Pedigree; Receptors Nicotinic; Somnambulism; FearReceptorsmedicine80 and overGeneticsHumansIctalGenetics(clinical)Amino Acid SequenceGenetics (clinical)Acetylcholine receptorAgedAged 80 and overNeuronsMutationEpilepsySeizure typesFearmedicine.diseaseAcetylcholinePedigreeNicotinic acetylcholine receptorNicotinic agonistEndocrinologyMutationnAChR patch-clamp ADNFLE sleep-related epilepsy M1 TM1 ACh nicotineSettore MED/26 - NeurologiaFemaleMissense
researchProduct

Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis

2000

Rippling muscle disease is a rare autosomal dominant disorder that may occur sporadically. In this report two patients presenting with rippling muscles followed by myasthenia gravis are described. Our first patient developed rippling muscles about 1 month after infection with Yersinia enterocolitica. Two years later myasthenia gravis appeared. Our second patient had a 2-year history of asthma prior to the onset of rippling muscles which preceded the myasthenic symptoms by 4-8 weeks. Acetylcholine receptor and anti-skeletal muscle antibody titers were positive in both patients. In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosu…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAzathioprineGastroenterologyMuscular DiseasesPhysical StimulationInternal medicineAzathioprineMyasthenia GravismedicineHumansGenetics (clinical)AsthmaAcetylcholine receptorbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseMyasthenia gravisNeurologyPyridostigmineRipplingPediatrics Perinatology and Child HealthImmunologyNeurology (clinical)medicine.symptombusinessImmunosuppressive AgentsMuscle ContractionPyridostigmine BromideMuscle contractionmedicine.drugNeuromuscular Disorders
researchProduct

Smoking cessation and variations in nicotinic acetylcholine receptor subunits alpha-5, alpha-3, and beta-4 genes.

2009

Background Evidence has recently accumulated that single nucleotide polymorphisms in the genetic region encoding the nicotinic acetylcholine receptor subunits α-5, α-3, and β-4 are associated with smoking and nicotine dependence. We aimed to determine whether these genetic variations are also predictive of smoking cessation. Methods Lifetime history of smoking was assessed by questionnaire at enrolment into a large epidemiological study of the German elderly population (ESTHER study). Cox proportional hazards modeling was applied in a retrospective cohort approach to determine the associations of individual polymorphisms and haplotypes with smoking cessation probability in 1446 subjects who…

AdultMalemedicine.medical_treatmentPopulationPhysiologySingle-nucleotide polymorphismNerve Tissue ProteinsReceptors NicotinicPolymorphism Single NucleotideGenetic determinismCohort StudiesmedicineHumanseducationBiological PsychiatryAgedGeneticseducation.field_of_studybusiness.industryProportional hazards modelHaplotypeMiddle AgedNicotinic acetylcholine receptorGenetic epidemiologyHaplotypesSmoking cessationFemaleSmoking CessationbusinessBiological psychiatry
researchProduct

Myasthenia gravis associated with Charcot-Marie-Tooth neuropathy: report of a case

1992

We report the case of a 24 year old woman who developed myasthenia gravis in the course of a mild form of Charcot-Marie-Tooth neuropathy. We describe the clinical manifestations together with the neurophysiological, pathological, serological findings and response to therapy and discuss the unusual association in the light of the relevant literature. © 1992 Masson Italia Periodici S.r.l.

Adultmedicine.medical_specialtyNeurologyResponse to therapySural nerve biopsySural NerveCharcot-Marie-Tooth DiseaseMyasthenia GravismedicineHumansReceptors CholinergicMild formPathologicalsural nerve biopsyNeuroscience (all)business.industryGeneral Neuroscienceanti-acetylcholine receptor antibodiemedicine.diseaseDermatologymyasthenia graviMyasthenia gravisSurgeryFemaleSettore MED/26 - NeurologiaNeurosurgeryNeurology (clinical)businessCharcot-Marie-Tooth neuropathy
researchProduct

Cellular Distribution and Expression of Cortical Acetylcholine Receptors in Aging and Alzheimer's Disease

1991

Ligand binding studies show marked reductions of nicotinic, but not of muscarinic binding sites in Alzheimer's disease. Using monoclonal antibodies we studied immunohistochemically the expression of the respective receptor proteins in the frontal cortex of middle-aged (55 +/- 5 yr) controls, age-matched controls (73 +/- 6 yr), and patients with Alzheimer's disease (74 +/- 5 yr). Density of nicotinic cholinoceptive neurons was 8000/mm3 for middle-aged controls and 4000/mm3 for age-matched controls, but only 900/mm3 in Alzheimer's brains (p less than 0.0001). Densities of muscarinic cholinoceptive and of Nissl-stained neurons were not significantly different between the groups, pointing to a …

Agingmedicine.medical_specialtyCORTEXGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceAlzheimer DiseaseInternal medicineMuscarinic acetylcholine receptormedicineHumansReceptors CholinergicBinding siteReceptorNEURONSAcetylcholine receptorCerebral CortexChemistryGeneral Neurosciencemedicine.diseaseCHOLINOCEPTORSCortex (botany)medicine.anatomical_structureEndocrinologyNicotinic agonistCerebral cortexAlzheimer's disease
researchProduct

Chapter 9 Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity

1996

Publisher Summary The neuronal nicotinic acetylcholine receptors (nAChRs) are differentially expressed on the somato-dendritic surface of hippocampal neurons. This chapter demonstrates that various ions and drugs play a crucial role in modulating the activity of neuronal nAChRs. Considering the diversity of the neurotransmitter receptors and their binding sites and the diversity of substances, which can act simultaneously as a primary agonist of one receptor and an allosteric modulator of a different receptor, an enormous variety of combinatorial possibilities can be achieved in the brain giving rise to very complex neuronal networks. The characterization of the diversity of many receptors …

AgonistAllosteric modulatorNicotinic agonistnervous systemChemistrymedicine.drug_classNeurotransmitter receptormedicineAlpha-4 beta-2 nicotinic receptorReceptorLong-term depressionNeuroscienceAcetylcholine receptor
researchProduct

Behavioral effects of different enriched environments in mice treated with the cholinergic agonist PNU-282987.

2013

Abstract Environmental enrichment is an experimental model in which rodents are housed in complex environments that favor lower levels of anxiety-like behavior. PNU-282987 (PNU) is a α7 nicotinic acetylcholine receptor agonist with beneficial effects on learning though its effects on anxiety are unclear. Our main aim was to carry out a study of its effects in NMRI ( n  = 96) mice reared in different environments: environmental enrichment (EE), Marlau™ cages (MC) and standard environment (SE). After a 4-month period, mice received acute treatment of PNU (2.5, 5 and 10 mg/kg) and were evaluated in the elevated plus-maze (EPM) and hole-board (HB). In the EPM, both EE and MC reared mice showed …

AgonistMalemedicine.medical_specialtyElevated plus mazealpha7 Nicotinic Acetylcholine Receptormedicine.drug_classAnxietyEnvironmentMotor ActivityDevelopmental psychologyBehavioral NeuroscienceBridged Bicyclo CompoundsMiceα7 nicotinic acetylcholine receptorInternal medicinemedicineAnimalsNicotinic AgonistsBeneficial effectsEnvironmental enrichmentBehavior AnimalExperimental modelGeneral MedicineNicotinic agonistEndocrinologyBenzamidesExploratory BehaviorCholinergicAnimal Science and ZoologyPsychologyInjections IntraperitonealBehavioural processes
researchProduct

Glycopyrronium bromide blocks differentially responses mediated by muscarinic receptor subtypes.

1993

To analyse the potency of glycopyrronium bromide in blocking responses mediated via subtypes of muscarinic receptors in vitro, we tried to determine its equilibrium dissociation constants at prejunctional muscarinic receptors inhibiting the twitch response of rabbit vas deferens (presumed M1 type), at M2 (paced at left atria), M3 (guinea pig ileum) muscarinic receptor subtypes and at the muscarinic receptor of the rabbit iris sphincter (not M1-M4, not m5). Glycopyrronium bromide shifted to the right the curve for inhibition of the twitch response induced by the agonist McN-A-343, and the methacholine-induced curves for inhibition of rat atrial contraction, and for tonic contraction of guine…

AgonistMalemedicine.medical_specialtymedicine.drug_classGuinea PigsIrisMuscarinic AntagonistsIn Vitro TechniquesModels BiologicalVas DeferensInternal medicineMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M4medicineAnimalsMethacholine CompoundsGlycopyrronium bromidePharmacologyChemistryVas deferens(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium ChlorideMuscarinic acetylcholine receptor M3ParasympatholyticsMuscarinic acetylcholine receptor M2HeartMuscle SmoothGeneral MedicineMuscarinic acetylcholine receptor M1GlycopyrrolateRatsEndocrinologymedicine.anatomical_structureFemaleRabbitsmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons

1998

In the present study, we demonstrate that choline, a precursor of acetylcholine (ACh) and a product of acetylcholine hydrolysis by acetylcholinesterase (AChE), acts as an efficient and relatively selective agonist of alpha7-containing nicotinic acetylcholine receptors (nAChR) in neurons cultured from the rat hippocampus, olfactory bulb and thalamus as well as in PC12 cells. Choline was able to activate postsynaptic and presynaptic alpha7 nAChRs, with the latter action resulting in the release of other neurotransmitters. Although choline was approximately one order of magnitude less potent than ACh (EC50 of 1.6 mM for choline and 0.13 mM for ACh), it acted as a full agonist at alpha7 nAChRs.…

AgonistN-MethylaspartatePatch-Clamp Techniquesmedicine.drug_classNicotinic AntagonistsMecamylaminePharmacologyHippocampusPC12 Cellscomplex mixturesCholineRats Sprague-DawleyMethylamineschemistry.chemical_compoundThalamusPostsynaptic potentialExcitatory Amino Acid AgonistsmedicineAnimalsCholineNicotinic AgonistsNootropic AgentsAcetylcholine receptorNeuronsGeneral NeuroscienceBungarotoxinsOlfactory BulbCholine acetyltransferaseAcetylcholinesteraseAcetylcholineRatsNicotinic agonistnervous systemchemistryBiochemistryDimethylphenylpiperazinium IodideAcetylcholinemedicine.drugEuropean Journal of Neuroscience
researchProduct

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

2005

The G protein coupling characteristics of a flag epitope-tagged orexin receptor type 1 (OX1R) was investigated in HEK293 cells. Immunoprecipitation of the OX1R and immunoblotting revealed interactions with Gq/G11 proteins as well as with Gs and Gi proteins. Stimulation with orexin-A did not affect the ability of the OX1R to coprecipitate Gq/G11 proteins, but it robustly elevated the intracellular concentration of Ca2+, [Ca2+]i. No changes in cAMP levels could be detected upon receptor stimulation. To get further insight into the functional correlation of G protein activation and Ca2+ signalling, we used baculovirus transduction to express chimeric G proteins, containing the Galphas protein …

AgonistReceptors Neuropeptidemedicine.drug_classG proteinBiologyKidneyBiochemistryCell LineReceptors G-Protein-CoupledGTP-binding protein regulatorsGTP-Binding ProteinsOrexin ReceptorsTransduction GeneticMuscarinic acetylcholine receptormedicineCyclic AMPHumansCalcium SignalingPharmacologyReceptor Muscarinic M3Neurotransmitter AgentsOrexinsDose-Response Relationship DrugNeuropeptidesIntracellular Signaling Peptides and ProteinsMuscarinic acetylcholine receptor M3Fusion proteinOrexin receptorCell biologyBiochemistryCalciumSignal transductionBaculoviridaeSignal TransductionBiochemical pharmacology
researchProduct